Radiological follow-up of adults hospitalised with pneumonia and SARS-CoV-2 infection, in Bristol UK, during the COVID19 pandemic

Gabriella Ruffino¹, Rachel L Williams², Shaney Barratt^{3,5}, Catherine Hyams^{1,3,4}

¹ Acute Medical Unit, Southmead Hospital, Bristol, UK, BS10 5NB

² Research and Innovation, North Bristol NHS Trust, Southmead Hospital, Bristol, UK, BS10 5NB

³ Academic Respiratory Unit, Learning and Research, Southmead Hospital, Bristol, UK, BS10 5NB

⁴ Schools of Population Health Sciences and Cellular and Molecular Medicine, University of Bristol, UK, BS2 8AE

⁵ Department of Respiratory Medicine, Southmead Hospital, Bristol, UK, BS10 5NB

Corresponding Author: Dr Catherine Hyams, MBBS BSc (Hons) PhD
Academic Respiratory Unit,
Learning and Research,
Southmead Hospital,
Bristol, UK, BS10 5NB
catherine.hyams@bristol.ac.uk

Running Title: Radiological follow up of pneumonia and SARS-CoV-2 infection

Keywords: Pneumonia, respiratory infection, COVID19, SARS-CoV-2, radiology

Funding: CH was funded by the National Institute for Health Research [NIHR Academic Clinical Fellowship (ACF-2015-25-002)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Declaration of Interests: CH is principal investigator of the Avon CAP study which is an investigator-led University of Bristol study funded by Pfizer and has previously received support from the NIHR in an academic clinical fellowship. The other authors have no relevant conflicts of interest to declare.

Word Count: 994/1000

1 **ABSTRACT**

2 For patients with pneumonia and COVID19 repeating chest radiography is recommend in
3 current British Thoracic Society (BTS) guidelines. Over two distinct time periods during the
4 COVID19 pandemic (Aug-Dec 2020, Jun-Aug 2021) we undertook an audit of 829 patients
5 hospitalised with infective radiological change (pneumonia=481, COVID19=348). 654/829
6 patients (79%) required radiological follow-up under BTS guideline criteria. 414/654 (63%)
7 were planned, 322/654 (49%) occurred and, of patients receiving radiological follow-up,
8 most occurred within BTS timelines (86%). Further audits should be conducted to ensure
9 BTS guidelines adherence, to avoid delay in diagnosing underlying malignancy or chronic
10 lung disease.

11

12 INTRODUCTION

13 Obstructing lung lesions can cause pneumonia, and lung cancer remains a leading cause of
14 cancer-related death [1]. Therefore British Thoracic Society (BTS) guidelines recommend
15 repeating chest radiography following community-acquired pneumonia (CAP) diagnosis at 6-
16 weeks in patients ‘at higher risk of underlying malignancy’ [2].

17

18 The radiological changes following SARS-CoV-2 infection are similar to those occurring
19 with other coronaviruses, which can result in chronic lung changes on imaging and reduced
20 lung function [3,4]. Recent BTS guidelines recommend repeating radiology at 12-weeks post-
21 discharge for patients with a COVID19 diagnosis [5]. We therefore audited patients
22 hospitalised with lobar consolidation due to CAP and opacities consistent with COVID19
23 pneumonitis to determine current BTS guideline adherence.

24

25 METHODS

26 Adults ≥ 18 years hospitalised to North Bristol NHS Trust were audited (1) from 1st August
27 until 30th November 2020, and (2) 1st June until 31st July 2021. Patients were screened to
28 identify those admitted with signs/symptoms of acute respiratory disease. Only patients with
29 consolidation or opacities consistent with COVID19 pneumonitis on admission radiology
30 were included. Pneumonia was defined as new radiological shadowing with no alternate
31 explanation in the opinion of a consultant radiologist [2]. COVID19 radiological change was
32 defined as multiple bilateral peripheral opacities or other change in keeping with SARS-CoV-
33 2 infection [3].

34

35 Clinical data were collected from medical records. Patient eligibility for repeat radiology was
36 determined separately by two authors: if disagreement occurred then the case was discussed.

In both pneumonia and COVID19, patient follow-up was classified as under hospital team (where radiology had to be booked) or GP (which required the discharge summary indicate repeat radiology was required). Follow-up was assessed at 6- or 12-weeks for lobar pneumonia and bilateral COVID19 pneumonitis respectively.

41

Categorical variables were presented as counts with percentages; continuous data as means and standard deviations (SD) if normally distributed and medians and interquartile range (IQR) if not normally distributed. Proportions were compared using Chi-squared testing; comparison of medians using Mann-Whitney U-Test.

46

47 RESULTS

From Aug-Dec 2020, 308 adults were hospitalised with lobar pneumonia and 249 with COVID19 pneumonitis. In June-Aug 2021, fewer adults were hospitalised with CAP (173) or COVID19 pneumonitis (99) (Figure One). Patient demographics are listed in Table One. COVID19 patients admitted from June-Aug 2021 were younger than those hospitalised in Aug-Dec 2020 ($P=0.036$). In both time periods, a high proportion of patients were deemed eligible for follow-up radiology (75% CAP versus 81% COVID19 Aug-Dec 20; and, 75% versus 93% COVID19 Jun-Aug 21). However, in both audit periods fewer CAP patients had radiology follow-up planned compared to COVID19 patients (54% versus 69%, and 62% versus 78% respectively) (Table Two). Of those with follow-up planned, most (80%) had this planned under the hospital team.

58

Table 1: Characteristics of Patients Hospitalised with Radiologically Proven Respiratory Infection

Characteristic	Cohort One (Aug-Dec 2020)			Cohort Two (June-Aug 2021)		
	Pneumonia N =308	COVID19 N =249	Total Cohort N =557	Pneumonia N =173	COVID19 N =99	Total Cohort N =272
Age (years) - median (IQR)	80.0 (68.0–87.4)	62.8 (54.2–76.9)	73.7 (59.4-83.9)	75.6 (61.8–85.7)	48.5 (35.0–59.6)	67.1 (48.5-81.7)
Male Gender – N (%)	159 (51.6)	156 (62.7)	315 (56.6)	92 (53.2)	62 (62.6)	154 (56.6)
Care home resident – N (%)	48 (15.6)	11 (4.4)	59 (10.6)	10 (5.8)	0 (0)	10 (3.7)
Smoking – N (%)						
Current	43 (14.0)	8 (3.2)	51 (9.2)	15 (8.7)	5 (5.1)	20 (7.4)
Ex-smokers	130 (42.2)	113 (45.4)	243 (43.6)	94 (54.3)	36 (36.4)	130 (47.8)
Unknown	62 (20.1)	32 (12.9)	94 (16.9)	13 (7.5)	14 (14.1)	27 (9.9)
Comorbidity Scores – N (%)						
Rockwood Frailty 0-4	120 (39.0%)	203 (81.5%)	323 (58.0%)	103 (59.5)	89 (89.9)	192 (70.5)
Rockwood Frailty 5-9	188 (61.0%)	46 (18.5%)	234 (42.0%)	70 (40.5)	10 (10.1)	80 (29.4)
CCI - median (IQR)	5 (4 - 7)	3 (1 - 4)	4 (2 - 6)	4 (2 - 6)	1 (0 - 3)	3 (1-5)
Respiratory – N (%)						
Any	140 (54.5)	68 (27.3)	208 (37.3)	81 (46.8)	28 (28.3)	109 (40.1)
COPD	95 (30.8)	19 (7.6)	114 (20.5)	45 (26.0)	<5 (<5.1)	49 (18.0)
Asthma	35 (11.4)	39 (15.7)	74 (13.3)	34 (19.7)	22 (22.2)	56 (20.6)
Other *	35 (11.4)	16 (6.4)	51 (9.2)	14 (8.1)	<5 (<5.1)	16 (5.9)
Cardiovascular – N (%)						
CCF	54 (17.5)	16 (6.4)	70 (12.6)	21 (12.1)	<5 (<5.1)	24 (8.8)
Ischaemic Heart Disease	62 (20.1)	32 (12.9)	94 (16.9)	24 (13.9)	<5 (<5.1)	28 (10.3)
Neurological – N (%)						
CVA/TIA	39 (12.7)	18 (7.2)	57 (10.2)	21 (12.1)	0 (0)	21 (7.7)
Dementia	40 (13.0)	7 (2.8)	47 (8.4)	12 (6.9)	0 (0)	12 (4.4)
Cognitive impairment	21 (6.8)	7 (2.8)	28 (5.0)	11 (6.4)	0 (0)	11 (4.0)
Other chronic neurological condition ‡	20 (6.5)	10 (4.0)	30 (5.4)	7 (4.0)	<5 (<5.1)	8 (2.9)
Malignancy – N (%)						
None	257 (83.4)	233 (93.6)	490 (88.0)	151 (87.3)	93 (93.9)	244 (89.7)
Solid Organ Cancer	42 (13.6)	10 (4.0)	52 (9.4)	21 (12.4)	5 (5.1)	26 (9.6)
Haematological Malignancy	12 (3.6)	7 (2.9)	19 (3.5)	<5 (<2.8)	<5 (<5.1)	<5 (<1.8)

* Includes bronchiectasis, pulmonary fibrosis, and other chronic respiratory conditions

‡ Includes Parkinson's disease, Huntingdon's disease, and other chronic neurological conditions not including CVA, TIA, Dementia or Cognitive Impairment

CCF, congestive cardiac failure; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; TIA, Transient Ischaemic Attack

1 Repeat radiological examination occurred in 49% eligible patients, and 42% underwent
2 investigation within BTS guideline timeframe (Table Two). 30% COVID19 patients admitted
3 in June-Aug 2021 received follow-up per guidelines when arranged under the hospital team;
4 in all other patient groups approximately 80% patients with hospital follow-up arranged
5 underwent such follow-up. Patients with GP led follow-up tended to be less likely to receive
6 follow-up within guideline criteria ($P=0.003$); although, there are small numbers in this audit.

7

1 **Table 2: Radiological follow-up of patients with pneumonia and COVID19**

2

Radiological Follow-Up	Cohort One (Aug-Dec 2020)			Cohort Two (June-Aug 2021)		
	Pneumonia N =308	COVID19 N =249	P-value	Pneumonia N =173	COVID19 N =99	P-value
Patients Eligible under BTS Guidelines[†] - N (%)						
Not eligible	77/308 (25)	48/249 (20)	-	43/173 (25)	7/99 (7)	
Eligible for follow-up	231/308 (75)	201/249 (81)	-	130/173 (75)	92/99 (93)	
Plan on Discharge - N (%)						
No follow-up booked	106/231 (46)	63/201 (31)	0.0001	49/130 (38)	20/92 (22)	0.0116
Self-discharge before follow-up booked	1/231(0)	0/201 (0)	NS	1/130 (1)	0/92 (0)	NS
Radiology plan implemented	124/231 (54)	138/201 (69)	0.0015	80/130 (62)	72/92 (78)	0.0076
- Under hospital team	72/124 (58)	113/138 (82)	<0.0001	62/80 (78)	67/72 (93)	0.0097
- Under GP	43/124(35)	20/138 (14)	0.0002	11/80 (14)	5/72 (7)	NS
- Documented plan not to repeat radiology	9/124 (8)	5/138(4)	NS	7/80 (9)	0/72 (0)	NS
Follow-up Occurrence - N (%)						
Total patients undergoing repeat radiology	97/235 (41)	118/201 (59)	0.0004	64/130 (49)	43/92 (47)	NS
Follow-up occurred within timeframe	87/235 (37)	104/201 (52)	0.0017	60/130 (46)	25/92 (27)	0.0042
- Under hospital team	58/72 (81)	93/113 (82)	NS	51/62 (82)	20/67 (30)	<0.0001
- Under GP	29/43 (67)	11/20 (55)	NS	9/11 (82)	5/5 (100)	NS

3
4 [†] Patient eligibility for repeat chest radiograph under BTS guidelines[2,5] was determined separately by two authors, and where there was disagreement a discussion to
5 determine eligibility occurred.

6
7 GP, General Practitioner; NS, not-significant

DISCUSSION

Appropriate patient follow-up is important to detect early and potentially treatable respiratory disease. 2.5% of chest radiographs repeated <90 days of pneumonia diagnosis result in lung cancer diagnosis, with cancer diagnostics predicted to increase if radiographs were only repeated in patients >50 years [6]. COVID19 prompted new BTS guidelines advising repeated radiological investigation 12-weeks post-discharge to facilitate early diagnosis of chronic lung changes.

In this single-centre audit, fewer CAP patients eligible for radiological follow-up had documented plans before hospital discharge when compared to COVID19 patients. We found some changes in guideline adherence across the two audit periods, with planned follow-up for both COVID19 pneumonitis and CAP increasing between the audit periods. However, the proportion of COVID19 patients undergoing radiological follow-up decreased (59% versus 47%, $P=0.04$), whereas CAP follow-up slightly increased (41% versus 49%, $P=0.14$). Additionally, follow-up within timeframe increased in CAP patients but reduced in COVID19 patients. The time-period for COVID19 follow-up is longer than that for CAP, and therefore it is possible pressure on healthcare had more effect on COVID19 follow-up.

These changes in guideline adherence observed have no notable trend and it would be inappropriate to conclude definitive reasons for any changes. BTS CAP guidelines [2] are well established and 86% radiological follow-up occurring did so in timeframe, with minimal change between the two audit periods. This suggests guideline familiarity is not contributing to adherence. However, only 63% eligible patients had follow-up planned and there is clearly need for improvement, as this leaves a significant number of patients without appropriate follow-up to detect either lung malignancy or chronic lung disease early. Further to this, 18% of planned follow-up did not take place and this needs to be addressed.

There is sparse literature concerning radiology follow-up following pneumonia. An audit from 2015 suggested 43% patients ≥ 50 years had appropriate advice given regarding radiology follow-up, with 15% undergoing repeat imaging [7]. A previous local audit showed 51% (55/107) patients underwent radiological follow-up within 6-weeks of presentation [8]. This audit aligns with previous literature, suggesting 49% planned follow-up occurred: 42% within BTS timelines.

This audit has many strengths. Firstly, it was conducted at a University hospital with specialist respiratory services and recruited many patients with CAP and COVID19. We repeated the audit over two time periods, to determine if there was any change in BTS guideline adherence. There are some limitations, and this is a single-centre audit so results may not be generalisable. By necessity we audited time periods when the NHS was under considerable pressure, and therefore rates of appropriate follow-up may improve when services are not under such strain.

These data suggest BTS guideline adherence regarding radiological follow-up may be suboptimal, with room for improvement and consequently improved patient outcomes. This audit should be undertaken at additional hospitals, and potentially nationally, to ensure appropriate BTS guidelines adherence thereby avoiding delay in diagnosing underlying malignancy or chronic lung disease.

REFERENCES

- 1 Valvani A, Martin A, Devarajan A, *et al.* Postobstructive pneumonia in lung cancer. *Ann Transl Med* 2019;**7**:357. doi:10.21037/atm.2019.05.26
- 2 Lim WS, Baudouin SV, George RC, *et al.* BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 2009;**64 Suppl 3**:iii1-55. doi:10.1136/thx.2009.121434
- 3 George PM, Barratt SL, Condliffe R, *et al.* Respiratory follow-up of patients with COVID-19 pneumonia. *Thorax* 2020;**75**:1009–16. doi:10.1136/thoraxjnl-2020-215314
- 4 Rai DK, Sharma P, Kumar R. Post covid 19 pulmonary fibrosis. Is it real threat? *Indian J Tuberc* 2021;**68**:330–3. doi:10.1016/j.ijtb.2020.11.003
- 5 British Thoracic Society guidance on respiratory follow up of patients with a clinico-radiological diagnosis of COVID-19 pneumonia. 2020.<https://www.brit-thoracic.org.uk/covid-19/covid-19-information-for-the-respiratory-community/> (accessed 11 Dec 2021).
- 6 Tang KL, Eurich DT, Minhas-Sandhu JK, *et al.* Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. *Arch Intern Med* 2011;**171**:1193–8. doi:10.1001/archinternmed.2011.155
- 7 Chisholm C, Rai R, Kaushal N. Audit to assess the follow-up of community acquired pneumonia with chest radiographs. *Clin Radiol* 2016;**71**:S13. doi:10.1016/j.crad.2016.06.071
- 8 Burt H, Chandratreya L. Are follow-up chest x-rays being performed according to British Thoracic Society Guidelines on adults diagnosed radiologically with Community Acquired Pneumonia? <https://www.eposters.net/poster/are-follow-up-chest-x-rays-being-performed-according-to-british-thoracic-society-guidelines-on> (accessed 11 Dec 2021).

AUTHOR CONTRIBUTIONS

CH, SB and GR generated the research questions. GR and CH undertook data collection and act as data verifiers. CH, GR, RW and SB contributed to the data analysis and prepared the manuscript for publication.

ACKNOWLEDGEMENTS

We would like to acknowledge the support of the IT team at North Bristol NHS Trust in undertaking this audit.

DATA SHARING

No additional data available.

FIGURE LEGENDS

Figure One: Study Flow Diagram

n this audit of adults hospitalised at Southmead hospital, there were (A) 557 adults in Aug-Dec 2020 and (B) 272 adults in Jun-July 2021 with confirmed lobar pneumonia or pneumonitis on their initial chest radiology.

aLRTD, acute lower respiratory tract disease; HAP, hospital acquired pneumonia

A **B**